Zhang Quan, Wang Jinghui, Zhang Shucai
Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute Beijing, China.
Int J Clin Exp Pathol. 2015 Feb 1;8(2):2195-8. eCollection 2015.
ALK rearrangement is a very rare subset of squamous cell cancer of lung and the efficacy of crizotinib treatment for these patients is lack of data. Here we report a case with squamous cell cancer of lung that harbored the ALK rearrangement was given crizotinib in the second-line therapy. A 55-year-old female patient was diagnosed with squamous cell carcinoma of lung by bronchoscopy biopsy with stage IV. The patient was given two cycles of chemotherapy and the response was progressive disease. After failure to chemotherapy, genotype testing showed wild-type EGFR/KRAS and ALK rearrangement positive. The patient was administered with crizotinib and had a partial response, and the progression-free survival was 6 months. The side effects were tolerable.
间变性淋巴瘤激酶（ALK）重排是肺鳞状细胞癌中非常罕见的一个亚型，目前缺乏关于克唑替尼治疗这些患者疗效的数据。在此，我们报告一例肺鳞状细胞癌患者，其存在ALK重排，在二线治疗中接受了克唑替尼治疗。一名55岁女性患者经支气管镜活检确诊为IV期肺鳞状细胞癌。该患者接受了两个周期的化疗，疗效为疾病进展。化疗失败后，基因检测显示表皮生长因子受体（EGFR）/ Kirsten大鼠肉瘤病毒癌基因（KRAS）为野生型，ALK重排阳性。该患者接受了克唑替尼治疗，出现部分缓解，无进展生存期为6个月。副作用可耐受。
